ALIVUS - Breakout in Daily timeframe
ALIVUS (Alivus Life Sciences Limited, formerly Glenmark Life Sciences) - Breakout
Breakout observed in daily timeframe of Alivus, the company has a very good chart pattern and is in a good uptrend and recently broke out with good volumes. The breakout has also been retested and sustained. There could be a good upside in this stock. The company also has good fundamentals as written below.
Fundamentals.
MCap 14,299Cr
Stock P/E 32.4
Industry P/E 31.6
ROCE 28.1%
ROE 21.1%
NPM 20.6%
PEG Ratio 1.69
Debt 16Cr
Reserves 2,514Cr
EPS 36.05
Promoter holding 75%
API contribution 9MFY24
Chronic : 69%
Acute : 31%
Key Therapeutic areas contribution 9MFY24
Diabetes : 4%
CVS : 41%
CNS : 17%
Pain Management : 6%
Others : 32%
Business segments
The company has two key segments - Generics and Complex APIs (92% of FY23 revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of FY23 revenue)
Breakout observed in daily timeframe of Alivus, the company has a very good chart pattern and is in a good uptrend and recently broke out with good volumes. The breakout has also been retested and sustained. There could be a good upside in this stock. The company also has good fundamentals as written below.
Fundamentals.
MCap 14,299Cr
Stock P/E 32.4
Industry P/E 31.6
ROCE 28.1%
ROE 21.1%
NPM 20.6%
PEG Ratio 1.69
Debt 16Cr
Reserves 2,514Cr
EPS 36.05
Promoter holding 75%
API contribution 9MFY24
Chronic : 69%
Acute : 31%
Key Therapeutic areas contribution 9MFY24
Diabetes : 4%
CVS : 41%
CNS : 17%
Pain Management : 6%
Others : 32%
Business segments
The company has two key segments - Generics and Complex APIs (92% of FY23 revenue) and Contract Development and Manufacturing Operations (CDMO) (8% of FY23 revenue)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.